Scholar Rock Holding Corporation
SRRK
Clasificación en acciones
#3425
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Precio por acción
$41.75
Capitalización bursátil
$5.08B
Cambio (1 día)
0.93%
Cambio (1 año)
48.19%
País
US
Comercio Scholar Rock Holding Corporation (SRRK)
Categoría
Healthcare
Ingresos de Scholar Rock Holding Corporation (SRRK)
Ingresos en Jun 2026 TTM: 0.00
Según los últimos informes financieros de Scholar Rock Holding Corporation, los ingresos actuales de la empresa (TTM) son 0.00. En 2023, la empresa obtuvo unos ingresos de 0.00 una disminución en comparación con los ingresos del año 2022, que fueron de $33.19M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Scholar Rock Holding Corporation desde 2016 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $33.19M | 76.41% |
| 2021 | $18.82M | 22.16% |
| 2020 | $15.40M | -24.83% |
| 2019 | $20.49M | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | -100.00% |
| 2016 | $379.00K | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
